Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population
Executive Summary
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.
You may also be interested in...
GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.